Pacific Biosciences Of California, Inc: Mitchell Blutt’s Consonance Capital Management Lp Opened Position

February 15, 2018 - By Hazel Jackson

 Pacific Biosciences Of California, Inc: Mitchell Blutt's Consonance Capital Management Lp Opened Position

Investors sentiment increased to 1.55 in 2017 Q3. Its up 0.53, from 1.02 in 2017Q2. It increased, as 16 investors sold Pacific Biosciences of California, Inc. shares while 17 reduced holdings. 15 funds opened positions while 36 raised stakes. 80.23 million shares or 4.63% more from 76.68 million shares in 2017Q2 were reported.

Ubs Asset Mgmt Americas reported 35,620 shares or 0% of all its holdings. Credit Suisse Ag owns 109,117 shares or 0% of their US portfolio. Barclays Public Limited Liability Company reported 2,401 shares. Royal Bancshares Of Canada reported 18,259 shares stake. Millennium Management Ltd accumulated 962,221 shares or 0.01% of the stock. 103,000 were accumulated by Alliancebernstein L P. Trellus Management Limited Liability has invested 3.78% of its portfolio in Pacific Biosciences of California, Inc. (NASDAQ:PACB). Consonance Cap Management L P stated it has 6.90M shares or 4.01% of all its holdings. Wells Fargo And Company Mn invested 0% in Pacific Biosciences of California, Inc. (NASDAQ:PACB). Rhumbline Advisers has 0% invested in Pacific Biosciences of California, Inc. (NASDAQ:PACB) for 108,584 shares. Panagora Asset Mgmt accumulated 174,634 shares. Ny State Common Retirement Fund holds 74,400 shares. Legal And General Group Public Ltd Liability invested 0% in Pacific Biosciences of California, Inc. (NASDAQ:PACB). Blair William And Co Il holds 27,811 shares. Moreover, Products Partners Ltd Liability Company has 0.07% invested in Pacific Biosciences of California, Inc. (NASDAQ:PACB) for 394,800 shares.

The New Mitchell Blutt’s Consonance Capital Management Lp Holding in Pacific Biosciences Of California, Inc

Consonance Capital Management Lp reported SC 13G/A form with the SEC for Pacific Biosciences Of California, Inc. Access it here: 000108514618000826. As reported by Mitchell Blutt’s Consonance Capital Management Lp, the filler owns 6.08% or 7,065,920 shares of the Health Care–company.

Pacific Biosciences Of California, Inc stake is new for [reportingPerson]. Date of activity: December 31, 2017. This shows Mitchell Blutt’s Consonance Capital Management Lp’s positive view for Pacific Biosciences Of California, Inc. For a hedge fund managing $513.80 million in assets and having 8+ experts this is interesting position.

The hedge fund is investor in the Health Care sector. In the manager’s last 13-F, we saw 12% of Mitchell Blutt’s Consonance Capital Management Lp’s portfolio is in the sector.

Pacific Biosciences Of California, Inc Institutional Sentiment

Filings show 84 investors own Pacific Biosciences Of California, Inc. The ownership in Q3 2015 is high, at Infinity of the outstanding shares. This is increased by 1946159. 40457308 were owned by these investors. 9 funds opened new Pacific Biosciences Of California, Inc stakes, 33 increased positions. There were 19 that closed positions and 28 reduced them.

Lee Ainslie Maverick Capital Ltd is an investor bullish on Pacific Biosciences Of California, Inc, owning 7456034 shares as of Q3 2015 for 0.47% of its portfolio. William C. Martin Raging Capital Management Llc owns 1566056 shares or 0.75% of its portfolio. NY Consonance Capital Management Lp have 3.22% of its portfolio for 6257861 shares. Further, Oracle Investment Management Inc reported stake worth 2.42% of its portfolio. The A8 Fiera Capital Corp owns 81564 shares. Pacific Biosciences Of California, Inc is less than 0.01% of its portfolio.

Business Profile

Pacific Biosciences of California, Inc. designs, develops and manufactures sequencing systems to help scientists resolve genetically complex problems. The Company is engaged in the development, manufacturing and marketing of an integrated platform for genetic analysis. Its Single Molecule, Real-Time (SMRT) technology enables single molecule, real-time detection of biological processes. It offers The SMRT Cell, Phospholinked nucleotides and The PacBio RS II and Sequel instruments. Its SMRT technology enables the observation of deoxyribonucleic acid (DNA) synthesis as it occurs in real-time by harnessing the natural process of DNA replication, which is actuated by the DNA polymerase. Its phospholinked nucleotides have a fluorescent dye attached to the phosphate chain of the nucleotide rather than to the base. The PacBio RS II and Sequel instruments include optics, automated liquid handling, a touchscreen control interface and computational hardware and software.

SEC Form 13G.

Mitchell Blutt’s Consonance Capital Management Lp website.

The stock increased 3.24% or $0.08 during the last trading session, reaching $2.55. About 731,215 shares traded. Pacific Biosciences of California, Inc. (NASDAQ:PACB) has declined 59.88% since February 15, 2017 and is downtrending. It has underperformed by 76.58% the S&P500.

Pacific Biosciences of California, Inc. designs, develops, and makes sequencing systems to resolve genetically complex problems. The company has market cap of $328.38 million. The company's single molecule real-time sequencing technology enables single molecule real-time detection of biological processes. It currently has negative earnings. It offers PacBio RS II and Sequel Systems that conducts, monitors, and analyzes biochemical sequencing reactions.

Pacific Biosciences of California, Inc. (NASDAQ:PACB) Ratings Coverage

Among 6 analysts covering Pacific Biosciences of California (NASDAQ:PACB), 2 have Buy rating, 0 Sell and 4 Hold. Therefore 33% are positive. Pacific Biosciences of California has $18.0 highest and $4.0 lowest target. $9.73’s average target is 281.57% above currents $2.55 stock price. Pacific Biosciences of California had 15 analyst reports since August 27, 2015 according to SRatingsIntel. The firm has “Hold” rating given on Tuesday, October 10 by Piper Jaffray. The stock of Pacific Biosciences of California, Inc. (NASDAQ:PACB) earned “Neutral” rating by M Partners on Friday, April 15. As per Friday, April 15, the company rating was initiated by First Analysis. The firm has “Hold” rating given on Friday, November 3 by First Analysis. On Thursday, September 28 the stock rating was downgraded by C.L. King to “Hold”. Maxim Group maintained it with “Buy” rating and $9 target in Thursday, August 27 report. The stock has “Buy” rating by Cantor Fitzgerald on Monday, January 4. The firm has “Buy” rating given on Monday, June 27 by CL King. The firm has “Buy” rating by Cantor Fitzgerald given on Thursday, August 27. Cantor Fitzgerald maintained the shares of PACB in report on Thursday, November 3 with “Buy” rating.

More notable recent Pacific Biosciences of California, Inc. (NASDAQ:PACB) news were published by: Bna.com which released: “Oxford Nanopore Technologies’ DNA Sequencers Don’t Infringe” on February 15, 2018, also Fool.com with their article: “What’s Behind Pacific Biosciences of California’s Sinking Fourth-Quarter Sales” published on February 02, 2018, Globenewswire.com published: “Pacific Biosciences Announces Outcome of First Phase of Patent Litigation …” on February 09, 2018. More interesting news about Pacific Biosciences of California, Inc. (NASDAQ:PACB) were released by: Seekingalpha.com and their article: “Battered Back Below $3, PacBio’s Shares Offer High-Risk Upside” published on February 08, 2018 as well as Prnewswire.com‘s news article titled: “Biotech Stocks’ Research Reports Released on OvaScience, Pacific Biosciences …” with publication date: February 14, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.